<AsiaNet> Actemra: Roche's Novel Rheumatoid Arthritis Drug Shows Substantial
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Benefits for Patients in OPTION Study
(BASEL, June 15 AsiaNet= 연합뉴스)
New Data Supports IL-6 Receptor Inhibition as a Key Component in
Controlling Inflammation From RA
Roche today announced significant results from 'OPTION'(1), the first
rheumatoid arthritis multinational phase III study of Actemra (tocilizumab)
outside of Japan. The data presented at the EULAR(2) meeting in Barcelona,
Spain, showed that patients who received Actemra in combination with
methotrexate achieved rapid and significant improvement in their signs and
symptoms of rheumatoid arthritis when compared to patients receiving
methotrexate alone.
In the 24-week study, four times the number of patients in the Actemra
group experienced 50% improvement in disease symptoms (ACR50(3) response)
compared to the control group (44% vs 11%). More than ten times the number of
Actemra patients achieved 70% improvement in disease signs and symptoms (ACR70
response) compared to the control group (22.0% vs 2.0%). In addition, 28% of
patients achieved the ultimate goal of remission(4) in the Actemra group vs
only 1% of patients in the control group.
"The efficacy of IL-6 receptor inhibition in this study confirms the
critical role of IL-6 in the causal pathways of rheumatoid arthritis. On this
basis, the profound clinical success observed with tocilizumab by targeting a
novel pathway is extremely encouraging as is the opportunity for rheumatoid
arthritis patients to benefit from a potential new treatment option," commented
lead investigator, Professor Josef Smolen.
"The detailed data from the OPTION study, together with the first data from
the TOWARD study announced last week, show a great benefit for rheumatoid
arthritis patients. We look forward to further results from our extensive
multinational Phase III development programme later this year" commented
William Burns, CEO Division Roche Pharmaceuticals.
Other parameters measured included C-reactive protein (CRP), a marker of
inflammation, fatigue and haemoglobin. Patients in the 8mg/kg Actemra group
showed a rapid normalisation of the CRP levels within 2 weeks while fatigue
scores showed that patients in the Actemra group experienced a reduction in
fatigue and a rapid improvement in haemoglobin levels. Low levels of
haemoglobin are usually associated with anaemia which makes patients feel tired
and lacking in energy.
About the OPTION study
The OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate
respONders) study was an international study involving 623 patients with
moderate to severe RA. In this 3-arm, randomized, double-blind study, patients
received tocilizumab intravenously (either 4mg/kg or 8mg/kg) every 4 weeks plus
methotrexate weekly or placebo infusions plus methotrexate weekly over a period
of 6 months.
Although higher efficacy was established at the higher dose (ACR20, 50 and
70 scores of 59%, 44% and 22% respectively in the 8mg/kg Actemra group),
patients treated with the lower dose of Actemra (4mg/kg) achieved ACR20, 50 and
70 scores of 48%, 32% and 12% respectively. Furthermore there was a reduction
in the Disease Activity Score (DAS) from week 2 onwards for both the 8mg/kg
(-3.43) and 4mg/kg (-2.68) Actemra groups compared to control (-1.55).
Remission of disease was demonstrated in 28% of patients treated with 8mg/kg of
Actemra and methotrexate vs 14% of patients treated with 4mg/kg of Actemra and
methotrexate vs 1% or patients receiving methotrexate alone.
Actemra was generally well tolerated with an adverse event (AE) profile
consistent with data reported in previous studies(5).
ENDS
Notes to Editors
About Actemra
Actemra is the first humanised interleukin-6 (IL-6) receptor inhibiting
monoclonal antibody and represents a novel mechanism of action to treat RA, a
disease with a high unmet medical need. Roche and Chugai are collaborating on a
phase III clinical development programme in RA running outside Japan, with more
than 4000 patients enrolled in 41 countries including several European
countries and the USA. In Japan, Actemra was launched in June 2005 as a therapy
for Castleman's disease and in April 2006 filed for the additional indications
of rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis.
About rheumatoid arthritis
Rheumatoid arthritis is a progressive, systemic autoimmune disease
characterized by chronic inflammation of multiple joints and fatigue as well as
the possibility of osteoporosis, anaemia, and lung, skin and liver effects.
This inflammation causes pain, stiffness and swelling, resulting in loss of
joint function due to destruction of the bone and cartilage, often leading to
progressive disability. Further, as chronic inflammation continues, there may
be shortening of life expectancy as a result of effects on major organ systems.
After 10 years, less than 50% of patients can continue to work or function
normally on a day to day basis. RA affects more than 21 million people
worldwide.
About Roche in rheumatoid arthritis
One of the most important drivers for growth at Roche over the next few
years is expected to be the company's emerging franchise in autoimmune diseases
with rheumatoid arthritis as the first indication. Following the launch of
MabThera(R) (rituximab) there are a number of projects in development,
potentially allowing Roche to build on further opportunities. MabThera is the
first and only selective B-cell therapy for RA, providing a fundamentally
different treatment approach by targeting B cells, one of the key players in
the pathogenesis of RA. Actemra is Roche's second novel medicine and is a
humanised monoclonal antibody to the interleukin-6 (IL-6) receptor, inhibiting
the activity of IL-6 , a protein that plays a major role in the RA inflammation
process. Actemra is the result of research collaboration by Chugai and is being
co-developed globally with Chugai. Additional projects creating a rich pipeline
include compounds in Phase I, II and III clinical trials. Notably, ocrelizumab,
a fully humanised anti-CD20 antibody, is just entering phase III development
for RA.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, a market leader
in virology and active in other major therapeutic areas such as autoimmune
diseases, inflammation, metabolism and central nervous system. In 2006 sales by
the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the
Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs
approximately 75,000 worldwide and has R&D agreements and strategic alliances
with numerous partners, including majority ownership interests in Genentech and
Chugai. Additional information about the Roche Group is available on the
Internet at www.roche.com
All trademarks used or mentioned in this release are protected by law.
Further information:
- Roche & Autoimmune diseases: www.roche.com/med_events_mb1106
Roche Group Media Office:
Phone: +41-61-688-8888 / e-mail: basel.mediaoffice@roche.com
- Daniel Piller (Head of Roche Group Media Office)
- Katja Prowald (Head of Science Communications)
- Martina Rupp
- Baschi Durr
- Claudia Schmitt
On site contacts:
Roche
Jennifer Wilson
International Communications Manager
Tel: +41-79-619-1765
Cohn & Wolfe
Jeremy Clark : Tel: +44-7834308958
Nicole Moores (UK): Tel : +44-207-331-5337
References:
(1) OPTION refers to the tOcilizumab Pivotal Trial in methotrexate
Inadequate respONders
(2) European League Against Rheumatism
(3) The ACR response is a standard assessment used to measure patients'
responses to anti-rheumatic therapies, devised by the American College
of Rheumatology (ACR). It requires a patient to have a defined
percentage reduction in a number of symptoms and measures of their
disease. For example, a 20%, 50% or 70% level of reduction (the
percentage of reduction of RA symptoms) is represented as ACR20, ACR50
or ACR70. An ACR70 response is exceptional for existing treatments and
represents a significant improvement in a patient's condition.
(4) Disease activity is measured by a Disease Activity Score (DAS), where
low disease activity is defined as DAS 28 less than or equal to 3.2
and remission is defined as DAS 28 less than or equal to 2.6
(5) Maini RN, Taylor PC, Szechinski J et al., on behalf of the CHARISMA
Study Group. Double-blind randomised controlled clinical trial of the
interleukin-6 receptor antagonist, tocilizumab, in European patients
with rheumatoid arthritis who had an incomplete response to
methotrexate. Arthritis Rheum. 2006 Sep;54(9):2817-29.
SOURCE: Roche
CONTACT: Jennifer Wilson,
International Communications Manager of Roche,
+41-79-619-1765;
Daniel Piller (Head of Roche Group Media Office),
Katja Prowald (Head of Science Communications),
Martina Rupp,
Baschi Durr,
Claudia Schmitt,
+41-61-688-8888,
basel.mediaoffice@roche.com,
all of Roche Group Media Office; or
Jeremy Clark,
+44-7834308958, or
Nicole Moores (UK),
+44-207-331-5337,
both of Cohn & Wolfe
Web sites: http://www.roche.com
http://www.roche.com/med_events_mb1106
anet1@yna.co.kr
<모바일로 보는 연합뉴스 7070+NATE/ⓝ/ez-i>
<저작권자(c)연합뉴스. 무단전재-재배포금지.>
Copyright © 연합뉴스. 무단전재 -재배포, AI 학습 및 활용 금지
- 대법, 견미리 남편 주가조작 무죄 파기…"중요사항 거짓기재" | 연합뉴스
- 횡단보도 건너던 50대 남매, 배달 오토바이에 치여 사망(종합) | 연합뉴스
- 30년 된 서울대공원 리프트 추억 속으로…곤돌라로 교체 속도 | 연합뉴스
- "올림픽에 오지 마세요"…파리 시민들, SNS로 보이콧 운동 | 연합뉴스
- '뚝배기 라면'·'맞춤 전통의상' 준비…우즈베크의 국빈 대접 | 연합뉴스
- 홍준표 "총선 망친 주범들이 당권 노린다"…한동훈 저격 | 연합뉴스
- 군가 맞춰 춤춰볼까…6살 루이 왕자 英왕실 행사 또 '신스틸러' | 연합뉴스
- '제자 성폭행' 성신여대 前교수 2심 징역 4년…1년 늘어 | 연합뉴스
- '명품시계' 태그호이어, 해킹으로 한국 고객 정보 2천900건 유출 | 연합뉴스
- "강간범보다 피해자 낙태 형량이 더 높아진다" 브라질 부글 | 연합뉴스